GFG Capital LLC Has $65,000 Holdings in Eli Lilly and Company $LLY

Key Points

• GFG Capital LLC significantly reduced its holdings in Eli Lilly and Company by 88.4%, now owning just 84 shares valued at $65,000.
• Several other institutional investors have increased their stakes in Eli Lilly, with Brighton Jones LLC raising its position by 22.0%.
• Analysts have issued mixed ratings for Eli Lilly, with one strong-buy, fourteen buy, and ten hold ratings, and a consensus price target of $948.56.

GFG Capital LLC lessened its stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 88.4% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 84 shares of the company's stock after selling 640 shares during the quarter. GFG Capital LLC's holdings in Eli Lilly and Company were worth $65,000 as of its most recent filing with the SEC.

Several other large investors also recently made changes to their positions in LLY. Brighton Jones LLC boosted its stake in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company's stock worth $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC boosted its stake in shares of Eli Lilly and Company by 2.8% during the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company's stock worth $1,136,000 after acquiring an additional 40 shares in the last quarter. Wedge Capital Management L L P NC boosted its stake in shares of Eli Lilly and Company by 13.9% during the 1st quarter. Wedge Capital Management L L P NC now owns 738 shares of the company's stock worth $610,000 after acquiring an additional 90 shares in the last quarter. Covestor Ltd boosted its stake in shares of Eli Lilly and Company by 24.9% during the 1st quarter. Covestor Ltd now owns 426 shares of the company's stock worth $352,000 after acquiring an additional 85 shares in the last quarter. Finally, GAMMA Investing LLC boosted its stake in shares of Eli Lilly and Company by 25.8% during the 1st quarter. GAMMA Investing LLC now owns 18,000 shares of the company's stock worth $14,866,000 after acquiring an additional 3,696 shares in the last quarter. Institutional investors own 82.53% of the company's stock.

Analyst Ratings Changes

Several analysts recently weighed in on the company. Leerink Partnrs downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Thursday, August 7th. Daiwa Capital Markets downgraded Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 target price for the company. in a research note on Sunday, August 17th. Wall Street Zen downgraded Eli Lilly and Company from a "strong-buy" rating to a "buy" rating in a research note on Saturday, September 20th. Leerink Partners restated a "market perform" rating and set a $715.00 target price on shares of Eli Lilly and Company in a research note on Thursday, August 7th. Finally, Berenberg Bank restated a "hold" rating and set a $830.00 target price (down previously from $970.00) on shares of Eli Lilly and Company in a research note on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and ten have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $948.56.

Eli Lilly and Company Trading Up 1.0%

Shares of LLY opened at $854.40 on Friday. Eli Lilly and Company has a 1 year low of $623.78 and a 1 year high of $937.00. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The stock has a 50 day simple moving average of $740.99 and a 200-day simple moving average of $766.49. The stock has a market cap of $808.66 billion, a PE ratio of 55.84, a PEG ratio of 1.18 and a beta of 0.47.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $6.31 earnings per share for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same period last year, the firm posted $3.92 EPS. The business's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Transactions at Eli Lilly and Company

In other news, Director J Erik Fyrwald acquired 1,565 shares of the firm's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $642.33 per share, for a total transaction of $1,005,246.45. Following the transaction, the director owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. This represents a 2.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Daniel Skovronsky acquired 1,000 shares of the firm's stock in a transaction on Tuesday, August 12th. The stock was purchased at an average price of $634.40 per share, for a total transaction of $634,400.00. Following the completion of the transaction, the executive vice president directly owned 137,660 shares in the company, valued at approximately $87,331,504. The trade was a 0.73% increase in their position. The disclosure for this purchase can be found here. In the last three months, insiders purchased 4,514 shares of company stock worth $2,894,841. Corporate insiders own 0.13% of the company's stock.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.